SB

Sunilendu Bhushan Roy

Active Director Additional Director DIN 07449487
DIN 07449487 First appointment Feb 2016 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 1 historical roles
Total affiliations 4 Since Feb 2016
Shareholding value •••• Premium profile

About Sunilendu Bhushan Roy

Data last updated:

Sunilendu Bhushan Roy is an Additional Director at Intelliscend Nddr Private Limited (since 2019), Managing Director at Intelliscend Pharma Research And Consultancy Private Limited (since 2019) and Director at Reakiro Hempire India Private Limited (since 2021). The companies operate in Pharma and Trading. The 2 current companies with reported revenue have a combined latest revenue of ₹3.44 Cr; the largest is Intelliscend Nddr Private Limited at ₹2.77 Cr (FY 2024). Earlier, Sunilendu Bhushan Roy was a Director at Ascent Innovative Medicines Private Limited (2016–2019).

DIN 07449487
Primary Designation Additional Director
Industry Pharma
First Appointment 24 Feb 2016
Oldest Company Age 13 yrs
Largest company Intelliscend Nddr Private Limited · ₹2.77 Cr (FY 2024)
Combined revenue ₹3.44 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Intelliscend Nddr Private Limited U24230MH2019PTC323470
Additional Director20 Nov 20192019₹2.77 Cr (FY 2024)Active
Managing Director20 Nov 20192013₹67.2 Lakh (FY 2023)Active
Director10 Mar 20212021Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director24 Feb 20162016₹9.6 Lakh (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Intelliscend Nddr Private Limited
Reakiro Hempire India Private Limited
Intelliscend Pharma Research And Consultancy Private Limited
Ascent Innovative Medicines Private Limited
Premium access

Shareholding and investment profile for Sunilendu Bhushan Roy

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sunilendu Bhushan Roy

Sunilendu Bhushan Roy currently holds 3 directorships: Intelliscend Nddr Private Limited (Additional Director, since 20 Nov 2019, revenue ₹2.77 Cr (FY 2024)); Intelliscend Pharma Research And Consultancy Private Limited (Managing Director, since 20 Nov 2019, revenue ₹67.2 Lakh (FY 2023)); Reakiro Hempire India Private Limited (Director, since 10 Mar 2021).

Sunilendu Bhushan Roy was first appointed on 24 Feb 2016 as Director at Ascent Innovative Medicines Private Limited. The most recent appointment on record is 10 Mar 2021 at Reakiro Hempire India Private Limited.

The 2 current companies of Sunilendu Bhushan Roy that report revenue have a combined latest revenue of ₹3.44 Cr: Intelliscend Nddr Private Limited ₹2.77 Cr (FY 2024); Intelliscend Pharma Research And Consultancy Private Limited ₹67.2 Lakh (FY 2023).

Sunilendu Bhushan Roy held 1 earlier board appointment: Ascent Innovative Medicines Private Limited (Director, 24 Feb 2016 to 25 Jun 2019).

The current boards of Sunilendu Bhushan Roy's companies include Kalpak Balkrishana Vartak (Intelliscend Nddr Private Limited), Manmohan Padamsingh Negi (Intelliscend Nddr Private Limited), Shashank Sunilendu Roy (Intelliscend Nddr Private Limited), Arti Rajan Potdar (Intelliscend Pharma Research And Consultancy Private Limited), Reena Roy (Intelliscend Pharma Research And Consultancy Private Limited), Shruti Roy (Intelliscend Pharma Research And Consultancy Private Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available